Latest News
Sionna Therapeutics receives approval from US Food and Drug Administration for Investigational New Drug application of SION-638
8 December 2022 - Sionna Therapeutics, a US-based life sciences company, announced on Wednesday. that it has received approval from the US Food and Drug Administration (FDA) for its Investigational New Drug application (IND) for SION-638, a novel sma...
Accord Healthcare adds Bendamustine Lyo. Injection to range of chemotherapy drugs
8 December 2022 - Accord Healthcare, Inc., a US-based generic pharmaceutical company, announced on Wednesday that it has added Bendamustine Lyo. Injection to its range of chemotherapy drugs.The company's product is AP rated to Teva's Treand...
Novavax receives Health Canada approval for supplement to Nuvaxovid New Drug Submission
8 December 2022 - Novavax, Inc. (Nasdaq: NVAX), a US-based biotechnology company, developing and commercialising next-generation vaccines for serious infectious diseases, announced on Wednesday that Health Canada has approved a supplement to a New Dr...
Antengene Corporation names new chief medical officer
8 December 2022 - Antengene Corporation Limited (SEHK: 6996.HK), a China-based, commercial-stage global biopharmaceutical company, announced on Wednesday that it has named Amily Zhang as its new chief medical officer.Dr Zhang is to replace Dr Kevin L...
European Commission Grants Expanded Marketing Authorization for Gilead's Biktarvy for the Treatment of HIV in Pediatric Populations
7 December 2022 - - The European Commission has authorized a new low-dose tablet dosage form of Biktarvy (bictegravir 30 mg/emtricitabine 120 mg/tenofovir alafenamide 15 mg tablets) and an extension of the indication for Biktarvy to treat HIV in...